ly2066948 has been researched along with Leiomyoma* in 2 studies
2 other study(ies) available for ly2066948 and Leiomyoma
| Article | Year |
|---|---|
Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety.
Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation. Topics: Animals; Brain; Dose-Response Relationship, Drug; Drug Design; Estrogens; Female; Humans; Leiomyoma; Models, Chemical; Ovary; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Software; Structure-Activity Relationship | 2007 |
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. 16 (LY2066948-HCl) binds with high affinity to estrogen receptors alpha and beta (ERalpha and ERbeta, respectively) and is a potent uterine antagonist with minimal effects on the ovaries as determined by serum biomarkers and histologic evaluation. Topics: Animals; Binding Sites; Biological Availability; Cell Line; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Leiomyoma; Mammary Glands, Animal; Models, Molecular; Naphthalenes; Organ Size; Ovary; Piperidines; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Uterine Neoplasms; Uterus | 2005 |